3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Neoplasms
4
Healthy Participants
2
Carcinoma, Non-Small-Cell Lung
2
Advanced Solid Tumor
2
cMET-dysregulated Advanced Solid Tumors
1
Solid Tumor, Adult
1
Solid Tumor
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Prostatic Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Liver Cirrhosis
1
Leiomyosarcoma
1
Drug-drug Interaction,SHR3680
1
Breast Neoplasms
1
Advanced Solid Malignancies
1
Interventions
Doxorubicin
33
pembrolizumab
16
Gemcitabine
15
eribulin
10
Irinotecan
10
olaratumab
9
Trabectedin
9
pazopanib
8
Docetaxel
8
Injections
7
Cyclophosphamide
7
Nivolumab
6
Fluorouracil
6
anlotinib
5
Temozolomide
5
Ipilimumab
5
Ifosfamide
5
Bevacizumab
5
tazemetostat
4
ridaforolimus
4
Drug Therapy
4
Cetuximab
4
Carboplatin
4
toripalimab
3
surufatinib
3
spartalizumab
3
ganitumab
3
entrectinib
3
conatumumab
3
belinostat
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Sarcoma
×
Digoxin
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled